Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vir Biotechnology Inc V.VIR


Primary Symbol: VIR

Healthcare Biotechnology
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.


NDAQ:VIR - Post by User

Vir Biotechnology Inc > Experion Holdings are you alive?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Comment by Redearth7on Nov 12, 2020 11:50am
101 Views
Post# 31885337

RE:RE:RE:RE:RE:RE:RE:RE:RE:Experion Holdings are you alive?

RE:RE:RE:RE:RE:RE:RE:RE:RE:Experion Holdings are you alive?Hey D-FK (Rapidfire) your name suits you as your delousional and on going "foolish assuming ways".   D-FK  blame it on your parents some people just went meant to have brain damaged kids, betting your an only child cuz when your parents saw you they said WTF, so you come by your new name D-FK as its meant to be.

GF yourself fool...I wont beat you with my ugly stick cuz you've already suffered enough.  The more you post D-FK the more everyone will know you as D-FK so as mentioned earlier GFYS D-FK.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities